High-dose, high-precision radiation therapy safe, effective for solitary kidney cancer patients with only one kidney

(American Society for Radiation Oncology) Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. Findings will be presented in a news briefing today at 12 p.m. from the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Abstract OBJECTIVES: The site of cancer care delivery has been shown to be associated with the total cost of care. The magnitude of this effect in patients receiving expensive immuno-oncology (I-O) therapies has not been evaluated. We evaluated cost differentials between community-based and hospital-based outpatient clinics among patients receiving I-O therapies. STUDY DESIGN: This was a retrospective analysis utilizing Truven MarketScan Commercial and Supplemental Medicare claims databases. METHODS: Cost data for 3135 patients with non-small cell lung cancer, squamous cell carcinoma of the head and neck...
Source: The American Journal of Managed Care - Category: Health Management Authors: Tags: Am J Manag Care Source Type: research
CONCLUSION:: All renal tumors decreased in size slowly but continuously for years after stereotactic body radiation therapy. Renal cancer can be treated radically with stereotactic body radiation therapy as a radiosensitive tumor, but careful attention should be given in cases with solitary kidney. PMID: 30803362 [PubMed - in process]
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Tags: Technol Cancer Res Treat Source Type: research
This study aimed to investigate the involvement of mitochondrial cytochrome c-dependent apoptosis in the mechanism of action of a combination of paclitaxel, sorafenib, and RT in RCC and breast cancer. RCC and breast cancer cell lines were exposed to paclitaxel and sorafenib alone or combined in the presence of radiation, and cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The synergistic anticancer effects of the combination therapy on cell cycle and intracellular signaling pathways were estimated using flow cytometry and immunoblot analysis. RCC and breast cancer...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
Clear cell carcinoma is the most common form of renal cell carcinoma (RCC). Metastatic RCC is poorly responsive to treatment and has a bleak prognosis. Newer systemic agents have improved outcomes. Furthermore, their interaction with radiation treatment (RT) may provide further therapeutic options. RCC is considered to be radioresistant, however we report the case of a patient with progression on targeted therapy and immunotherapy who achieved a substantial and sustained local, and possibly abscopal, response to low dose palliative radiation therapy.Case Rep Oncol 2018;11:756 –762
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
AbstractAlthough nivolumab has been regarded as a standard agent for patients with previously treated advanced renal cell carcinoma (RCC), a significant proportion of these patients fail to achieve a response to nivolumab. In recent years, several studies have reported the favorable therapeutic impact of combined therapy with immune checkpoint inhibitors and radiotherapy on a wide variety of advanced malignant tumors, such as melanoma and lung cancer; however, the significance of this combined treatment for advanced RCC patients has not been well characterized. Here, we report two patients with metastatic RCC showing a mar...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Kidney cancer has been increasing by 1.7% annually. Renal cell carcinoma (RCC) is the most common kidney cancer, and can metastasize. Our aim is to analyze patients treated with Stereotactic Body Radiation Therapy (SBRT) on metastases from RCC.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
AbstractPurpose of the ReviewBrain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the manage...
Source: Current Neurology and Neuroscience Reports - Category: Neuroscience Source Type: research
Clear-cell renal cell carcinoma (ccRCC) is the major renal cell carcinoma subtype, but its postsurgical prognosis varies among individual patients. We used gene expression, machine learning (random forest variable hunting), and Cox regression analysis to develop a risk score model based on 15 genes to predict survival of patients with ccRCC in the The Cancer Genome Atlas dataset (N = 533). We validated this model in another cohort, and analyzed correlations between risk score and other clinical indicators. Patients in the high-risk group had significantly worse overall survival (OS) than did those in the low-risk gro...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
This study aimed to assess the benefit of SRT in the management of metastatic RCC patients.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Xiang-Rong Zhao, Guang-Lian Shan, Yong Zhang, Yong-Hua YuJournal of Cancer Research and Therapeutics 2018 14(8):260-262 For localized the incidence of renal cell carcinoma (RCC), nephrectomy is the standard treatment. As RCC is generally regarded as a radiation-resistant tumor, the value of postoperative adjuvant radiotherapy is controversial. However, with new advance in radiotherapy (i.e., three-dimensional conformal radiation therapy [3DCRT] and intensity-modulated radiation therapy [IMRT]), target volume delineation, intensity modulation in treatment planning, and treatment delivery are more accurate with fewer advers...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Radiation Therapy | Renal Cell Carcinoma | Urology & Nephrology